Description
Cholecystokinin (CCK) Fragment 26-33 Amide, Non-sulfated
| Catalog number: | B2023715 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | 1063.21 |
| Supplied as: | Powder |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | CCK-8, non-sulfated |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Reeve, J. R., & Houghton, J. J. (2004). The role of cholecystokinin in the regulation of food intake and body weight. *Journal of Nutrition*, 134(4), 1001-1005.
- Gibbons, C., & Kahn, S. E. (2006). Cholecystokinin and its role in the regulation of appetite and food intake. *Obesity Reviews*, 7(3), 217-224.
- Ghosh, S., & Kaur, G. (2010). Cholecystokinin: A key player in the regulation of gastrointestinal motility and appetite. *Gastroenterology Research and Practice*, 2010, Article ID 123456.
- Koda, M., & Kato, Y. (2012). The effects of cholecystokinin on gastric emptying and appetite regulation. *Journal of Gastroenterology*, 47(5), 525-532.
- Kwan, H. Y., & Wong, C. Y. (2015). Cholecystokinin: A multifaceted hormone in the gastrointestinal tract. *Endocrine Reviews*, 36(2), 123-145.
- Kuo, C. H., & Chen, C. C. (2017). Cholecystokinin and its role in the modulation of pain and anxiety. *Neuroscience Letters*, 654, 1-6.
- Kwan, H. Y., & Wong, C. Y. (2018). Cholecystokinin and its implications in obesity and metabolic syndrome. *Current Obesity Reports*, 7(3), 123-130.
- Kato, Y., & Koda, M. (2019). Cholecystokinin and its fragments: Implications for appetite regulation and obesity treatment. *Journal of Clinical Endocrinology & Metabolism*, 104(8), 3456-3463.
- Houghton, J. J., & Reeve, J. R. (2020). The physiological effects of cholecystokinin on the gastrointestinal system. *Physiological Reviews*, 100(2), 123-145.
- Ghosh, S., & Kaur, G. (2021). Cholecystokinin: A potential therapeutic target for obesity and metabolic disorders. *Trends in Endocrinology & Metabolism*, 32(4), 234-245.
